Mantle Cell Lymphoma

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the potential of immunotherapy in patients with mantle cell lymphoma (MCL).

Simon Rule, MD, PhD, discusses the current and potential use of BTK inhibitors for the treatment of patients with mantle cell lymphoma.

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses unmet needs in the treatment landscape of mantle cell lymphoma.

Jonathon B. Cohen, MD, discusses the potential benefit of offering deferred therapy to asymptomatic patients with mantle cell lymphoma.

Axicabtagene ciloleucel (axi-cel; Yescarta) is being evaluated in patients with relapsed or refractory mantle cell lymphoma—a rare B-cell non-Hodgkin lymphoma that contributes 4200 new patients in the United States each year.

Brad Kahl, MD, discusses the exciting new advancements on the horizon for the treatment of patients with mantle cell lymphoma.

Andre Goy, MD, shares insight on the new array of treatment options for mantle cell lymphoma and how to properly implement them.

Toby Eyre, MBChB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses the results of single-agent venetoclax (Venclexta) in patients with relapsed/refractory mantle cell lymphoma.

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the combination of biological therapies in the treatment of patients with relapsed mantle cell lymphoma (MCL).

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in mantle cell lymphoma (MCL).

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the evolution of treatment in mantle cell lymphoma (MCL).

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the potential of frontline ibrutinib (Imbruvica) in the treatment of patients with mantle cell lymphoma.

Talal Hilal, MB, BCh, discusses the findings of a meta-analysis of rituximab maintenance for patients with mantle cell lymphoma (MCL), and the approach to maintenance therapy in patients with MCL.

Talal Hilal, MB, BCh, assistant professor of medicine, Mayo Clinic, discusses a study of rituximab (Rituxan) maintenance in patients with mantle cell lymphoma (MCL) after induction chemoimmunotherapy.

Michael Wang, MD, discusses what he hopes to find in the ZUMA-2 trial and his belief that MCL can be cured in his lifetime.

Toby Eyre, MBChB, MRCP, consultant hematologist at Oxford University Hospitals NHS Foundation Trust, discusses venetoclax (Venclexta) monotherapy in patients with mantle cell lymphoma.

Toby Eyre, MBChB, MRCP, discusses the results of the phase I study with venetoclax in patients with poor-risk relapsed/refractory mantle cell lymphoma.

Andre Goy, MD, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses prognostic markers in mantle cell lymphoma (MCL).

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the ZUMA-2 trial in patients with relapsed/refractory mantle cell lymphoma.

Talal Hilal, MB, BCh, assistant professor of medicine, Mayo Clinic, discusses the meta-analysis of rituximab maintenance for patients with mantle cell lymphoma.

The CD19-targeted CAR T-cell product axicabtagene ciloleucel (axi-cel; Yescarta) is currently being investigated in patients with relapsed/refractory MCL in the ongoing ZUMA-2 trial.

Combining the BTK inhibitor ibrutinib (Imbruvica) with the PI3K inhibitor buparlisib induced an objective response in 18 of 37 patients with relapsed/refractory non-Hodgkin lymphoma.

Selina Chen-Kiang, PhD, professor of pathology and immunology, Weill Cornell Medicine, discusses CDK4 inhibition with palbociclib (Ibrance) in mantle cell lymphoma.

Selina Chen-Kiang, PhD, details the research being conducted with CDK4/6 inhibitors in mantle cell lymphoma.

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the efficacy of ibrutinib (Imbruvica) and acalabrutinib (Calquence) in patients with mantle cell lymphoma (MCL).